science
Amylyx and Biogen to Release Biotech Trial Results This Quarter
Stat reported upcoming data from Amylyx's Phase 3 study of avexitide and detailed results from Biogen's mid-stage Alzheimer's trial. The events form part of the publication's third-quarter biotech scorecard.
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Stat reported that Amylyx Pharmaceuticals will release results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia. The rare metabolic condition causes severe drops in blood sugar. Biogen announced results from a mid-stage clinical trial of diranersen, an Alzheimer’s disease treatment targeting the protein tau, in May.
Detailed data from the study will be presented on July 14 at the Alzheimer’s Association International Conference. These events appear in STAT’s biotech scorecard for the third quarter.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
